Previous 10 | Next 10 |
Image source: The Motley Fool. 22nd Century Group (NASDAQ: XXII) Q2 2022 Earnings Call Aug 09, 2022 , 10:00 a.m. ET Operator Continue reading For further details see: 22nd Century Group (XXII) Q2 2022 Earnings Call Transcript
22nd Century Group, Inc. (XXII) Q2 2022 Earnings Conference Call August 09, 2022 10:00 AM ET Company Participants Joe Schepers - Vice President of Communications & Investor Relations Jim Mish - Chief Executive Officer John Miller - President of Tobacco Busine...
The following slide deck was published by 22nd Century Group, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: 22nd Century Group, Inc. 2022 Q2 - Results - Earnings Call Presentation
22nd Century press release ( NASDAQ: XXII ): Q2 GAAP EPS of -$0.06 in-line. Revenue of $14.5M (+72.6% Y/Y) beats by $3.21M . The increase was due to increased contract manufacturing volumes as well as the addition of GVB Biopharma revenue for approximately half of ...
Strong Chicago Pilot Exceeded Expectations, Accelerates VLN ® Expansion in Colorado Accretive GVB Biopharma Acquisition Doubles Corporate Revenue and Expands Market Leading Hemp/Cannabis Capabilities Second Quarter Net Sales $14.5 Million, Up 73% from the Second Quarter...
22nd Century ( NASDAQ: XXII ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.06 (-100.0% Y/Y) and the consensus Revenue Estimate is $11.29M (+34.4% Y/Y). Over the last 3 months, EPS estimates h...
BUFFALO, N.Y., July 27, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, will host a live webcast on Tue...
Alan Sumler discusses his long cannabis positions and investing through a medical and historical lens. A rare opinion - Positive on Canada! Psychedelic and cannabis overlap. Playing options, balancing technical and fundamental analysis and problems with the way we cover cannab...
22nd Century Group (NASDAQ: XXII) is a biotechnology firm making plants like tobacco and cannabis less dangerous, more potent, and more lucrative. Recognizing the enormous potential that cannabis bioscience offers, the company -- 22CG for short -- undertook several funding rounds to...
Announces $35 Million Above Market Financing Bolsters Company’s Position with Ongoing Strategic Discussions BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) , a leading agricultural biotechnology company dedicated to imp...
News, Short Squeeze, Breakout and More Instantly...
22nd Century Group Inc Company Name:
XXII Stock Symbol:
NYSE Market:
22nd Century Group Inc Website:
Patented, Fully Water Dispersing, Biodegradable Solution for World's Most Littered Item Mocksville, North Carolina--(Newsfile Corp. - July 10, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction and contract manufacturing, today announce...
Mocksville, North Carolina--(Newsfile Corp. - July 9, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction and contract manufacturing, today announced a new agreement for full-scale commercial rollout of its VLN® reduced nicotine cont...
Mocksville, North Carolina--(Newsfile Corp. - June 25, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction and contract manufacturing, today announced a $1.5 million reduction in its secured debt via a paydown of the GVB secured promissor...